Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

被引：384

作者：

Hirsh, J ^{[1
]}

Warkentin, TE ^{[1
]}

Raschke, R ^{[1
]}

Granger, C ^{[1
]}

Ohman, EM ^{[1
]}

Dalen, JE ^{[1
]}

机构：

[1] Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada

来源：

CHEST | 1998年 / 114卷 / 05期

关键词：

D O I：

10.1378/chest.114.5_Supplement.489S

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：489S / 510S

页数：22

共 245 条

[1]

ABBOTT EC, 1966, CAN MED ASSOC J, V94, P1155

[2]

AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95

[3] Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia [J].

Amiral, J ;

MarfaingKoka, A ;

Wolf, M ;

Alessi, MC ;

Tardy, B ;

BoyerNeumann, C ;

Vissac, AM ;

Fressinaud, E ;

Poncz, M ;

Meyer, D .

BLOOD, 1996, 88 (02) :410-416

[4]

AMIRAL J, 1995, THROMB HAEMOSTASIS, V73, P21

[5] The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin [J].

Anand, S ;

Ginsberg, JS ;

Kearon, C ;

Gent, M ;

Hirsh, J .

ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (15) :1677-1681

[6] MOLECULAR-WEIGHT DEPENDENCY OF THE HEPARIN POTENTIATED INHIBITION OF THROMBIN AND ACTIVATED FACTOR-X - EFFECT OF HEPARIN NEUTRALIZATION IN PLASMA [J].

ANDERSSON, LO ;

BARROWCLIFFE, TW ;

HOLMER, E ;

JOHNSON, EA ;

SODERSTROM, G .

THROMBOSIS RESEARCH, 1979, 15 (3-4) :531-541

[7]

ANDRIUOLI G, 1985, HAEMOSTASIS, V15, P324

[8]

[Anonymous], 1994, Circulation, V90, P1631

[9] HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL [J].

ANTMAN, EM .

CIRCULATION, 1994, 90 (04) :1624-1630

[10]

Antman EM, 1996, EUR HEART J, V17, P971

← 1 2 3 4 5 6 7 8 9 10 →